Sol-Gel Technologies raised $33.1 million in an oversubscribed offering and received a patent extension for its topical drug SGT-610 until 2044. The company is progressing its Phase 3 clinical trial for SGT-610 targeting Gorlin syndrome, with top-line results expected in Q4 2026. Additionally, Sol-Gel signed an exclusive license deal with Sun Pharma for TWYNEO® commercialization in India, expanding its global reach. Financially, the company reported a net loss of $3.7 million for Q1 2026 but has sufficient cash to fund operations into early 2028.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
